GENTRAL FAX CENTER

JUN 03 2008

## AMGEN INC.

One Amgen Center Drive Thousand Oaks, CA 91320 (805) 499-5725

Telecopier Number: (805) 499-8011 or (805) 447-1090

DATE:

June 3, 2008

TO:

USPTO - Fax # 571-273-8300

Examiner: Teresa D. Wessendorf

Group Art Unit: 1639

FROM:

Timothy J. Gaul

Phone: (805) 447-2688

RE:

U.S. Patent Appln. Ser. No. 10/645,784

Filed: August 18, 2003

Entitled: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Inventors: Feige, et al. Group Art Unit: 1639 Our Ref: A-527E

#### Enclosed are the following:

1. <u>1 page</u> Amendment Transmittal
 2. <u>4 pages</u> Amendment and Response

Thank you, Timothy J. Gaul Reg. # 33,111

There are a total of 6 pages being transmitted. This transmission may contain confidential and/or privileged information intended solely for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If all pages are not received or if you have received this facsimile in error, please notify us immediately by calling (805) 447-6855.

## RECEIVED CENTRAL FAX CENTER NO. 8054998011

JUN 0 3 2008

#### PATENT APPLICATION

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL						Attomey's Docket No: A-527E				
Serial No.		Filing Date		Examiner		Group Art Unit				
10/645,7		Augt	ıst 18, 2003	Teresa D. Wesse	ndorf		1639			
In Re Application of Feige et al.										
For MODIFIED PEPTIDES AS THERAPEUTIC AGENTS										
TO THE COMMISSIONER FOR PATENTS:										
Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):										
One month of original due date (\$120.00)										
Two months of original due date (\$460.00)										
Three months of original due date (\$1,050.00)										
Four months of original due date (\$1,640.00)										
Five months of original due date (\$2,230.00)										
A response in connection with the matter for which this extension is requested:										
is filed herewith.										
□ has been filed.										
The seconds is the filing of a continuing application, the prior application having an express										
ab and a most conditioned on the granting of a filling date to the continuing appropriation.										
The accompanying papers include amended claims for which no additional fee is required.										
☐ The accompanying papers include amended claims the fee for which has been calculated as follows:										
CLAIMS AS AMENDED										
(1)	(2)	(3)	(4)	(5)		(6)			(7)	
`"	Claims	` '	Highest numbe		1				ditional Fee	
1	remaining		Previously paid	claims present	ŀ	Rate			LAC	
	After		for		1					
	amendment	1.01		1 0	x	\$50		\$	0.00	
Total Claims		Minus Minus		<del></del> _	1 x	\$210	=		0.00	
Indep. Claims	af a manification				1 7	\$370	=	\$	0.00	
First Appearance of a multiple dependent claim + \$370 = \$0.00  Total Additional Fee for this Amendment \$0.00										
2 is less than the entry is column 4 write "0" in column 5.										
1 44 If the "Uinheet Number Praylough Paid For" IN THIS SPACE IS (858 than 20, with 40 in this space.										
I was true with the sea to the province of the Point English THIS SPACE IS less than 3, write 3, 10 uns space.										
The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1. or a prior										
amendment or the number of claims originally filed.										
☐ The following other fees are incurred by the accompanying papers.										
Other:										
Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$ A duplicate copy of this petition is attached.										
☑ If an additional extension of time is required, please consider this a request therefore.										
The Commissioner is because authorized to charge any additional fees, which may be required by the										
accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.										
Please Send Future Correspondence To:										
21069 Amolly & House										
Timothy   Garl										
M/S 28-2-C Attorney/Agent for Applicant(s) Registration No.: 33,111										
AMGEN INC. Registration No.: 33,111										
One Amgen Center Drive Phone: (805) 447-2688										
Thousand Oaks, California 91320-1799, USA Date: June 3, 2008										

CERTIFICATE OF FACSIMILE TRANSMISSION

Thoraby certify that this paper (along with any referred to as builty added or enclosed) to being superinformation to the United States Potent of Interest Office on the June 3, 2007

Date

CERTIFICATE OF FACSIMILE TRANSMISSION

Interest of the Center of Cen

RECEIVED **GENTRAL FAX CENTER** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 03 2008

Applicant(s): Feige et al.

10/645,784 Serial No.:

Group Art Unit No.: 1639

Filed:

August 18, 2003

Examiner: Teresa D. Wessendorf

For:

MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527E

## AMENDMENT AND RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to telephone interviews with the Examiner on May 30th and June 2nd, 2008 regarding the above-identified patent application, the Applicants respectfully submit the claims appearing below.

Amendments to the Claims begin on page 2 of this paper Remarks/arguments begin on page 4 of this paper.

CERTIFICATE OF FACSIMILE TRANSMISSION

June 3, 2008